Compliance with FDA recommendations for pemoline.

Suppr

超能文献

作者信息

Sarkis Elias H

出版信息

J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):383; author reply 383. doi: 10.1097/01.CHI.0000037045.04952.A0.

DOI:10.1097/01.CHI.0000037045.04952.A0

PMID:12649623

Abstract

摘要

相似文献

Compliance with FDA recommendations for pemoline.

J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):383; author reply 383. doi: 10.1097/01.CHI.0000037045.04952.A0.

Pemoline in ADHD.

J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1649-50. doi: 10.1097/00004583-199712000-00007.

Pemoline (Cylert): market withdrawal.

CMAJ. 2000 Jan 11;162(1):106, 110.

An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):1018-24. doi: 10.1097/00004583-199608000-00012.

Photic responses in "minimal brain dysfunction".

Dis Nerv Syst. 1974 Aug;35(8):355-7.

Medication for attention deficit hyperactivity disorder: commentary and response.

J Am Coll Health. 1996 Jul;45(1):40-1; discussion 41-2. doi: 10.1080/07448481.1996.9937544.

[Attention deficit hyperactivity disorder in children].

J Pharm Belg. 2002 Mar-Apr;57(2):25-32.

[Stimulant therapy in children].

Pharmacopsychiatria. 1982 Nov;15(6):181-2. doi: 10.1055/s-2007-1019534.

A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.

J Am Acad Child Adolesc Psychiatry. 2004 Apr;43(4):420-9. doi: 10.1097/00004583-200404000-00008.

FDA-approved drugs to treat ADHD.

J Psychosoc Nurs Ment Health Serv. 2012 Mar;50(3):11-2. doi: 10.3928/02793695-20120127-01.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Compliance with FDA recommendations for pemoline.

J Am Acad Child Adolesc Psychiatry. 2003 Apr;42(4):383; author reply 383. doi: 10.1097/01.CHI.0000037045.04952.A0.

Pemoline in ADHD.

J Am Acad Child Adolesc Psychiatry. 1997 Dec;36(12):1649-50. doi: 10.1097/00004583-199712000-00007.

Pemoline (Cylert): market withdrawal.

CMAJ. 2000 Jan 11;162(1):106, 110.

An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.

J Am Acad Child Adolesc Psychiatry. 1996 Aug;35(8):1018-24. doi: 10.1097/00004583-199608000-00012.

Photic responses in "minimal brain dysfunction".

Dis Nerv Syst. 1974 Aug;35(8):355-7.

Medication for attention deficit hyperactivity disorder: commentary and response.

J Am Coll Health. 1996 Jul;45(1):40-1; discussion 41-2. doi: 10.1080/07448481.1996.9937544.

[Attention deficit hyperactivity disorder in children].

J Pharm Belg. 2002 Mar-Apr;57(2):25-32.

[Stimulant therapy in children].

Pharmacopsychiatria. 1982 Nov;15(6):181-2. doi: 10.1055/s-2007-1019534.

A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.

J Am Acad Child Adolesc Psychiatry. 2004 Apr;43(4):420-9. doi: 10.1097/00004583-200404000-00008.

FDA-approved drugs to treat ADHD.

J Psychosoc Nurs Ment Health Serv. 2012 Mar;50(3):11-2. doi: 10.3928/02793695-20120127-01.